Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Propanc Biopharma, Inc.
Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America
August 14, 2024
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors
July 17, 2024
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office
June 25, 2024
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
April 16, 2024
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office
January 16, 2024
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities
December 18, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP
December 13, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells
November 07, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia
August 15, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030
July 25, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
July 13, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors
July 05, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Provides Shareholder Update
June 22, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Announces Strategic Pharma Partnering Initiative
June 06, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCBD
Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe
May 25, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCBD
Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America
May 23, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Announces Reverse Stock Split
May 22, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer
March 28, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
March 16, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)
January 11, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén
December 15, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer
November 30, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer
November 15, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference
October 26, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17
October 12, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027
September 29, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Provides Shareholder Update
September 13, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment
September 08, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
OTC
PPCB
Propanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery Program
August 23, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
PPCB
Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office
August 16, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Tickers
PPCB
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.